TrialCancer2010

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

Grace K Dy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.